This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| FDA Center for Drug Evaluation and Research | |
|---|---|
| Name | Center for Drug Evaluation and Research |
| Native name | CDER |
| Formed | 1982 |
| Preceding1 | Bureau of Drugs |
| Jurisdiction | United States |
| Headquarters | Silver Spring, Maryland |
| Parent agency | Food and Drug Administration |
| Chief1 name | [Director] |
| Chief1 position | Director |
FDA Center for Drug Evaluation and Research is the principal human drug evaluation branch of the Food and Drug Administration, responsible for ensuring the safety, efficacy, and security of human pharmaceutical products. It evaluates new drug applications, oversees generic drug standards, manages postmarketing surveillance, and issues guidance shaping clinical research and regulatory policy. CDER interacts with pharmaceutical companies, academic institutions, international regulators, and legislative bodies to implement statutes and guidelines.
The center traces institutional roots to the early twentieth-century regulatory reforms following the Pure Food and Drug Act and the passage of the Federal Food, Drug, and Cosmetic Act, evolving through organizational iterations such as the Bureau of Chemistry and the Bureau of Drugs. Key regulatory milestones included the 1962 amendments influenced by the Thalidomide tragedy and the Kefauver hearings led by Senator Estes Kefauver, which culminated in strengthened premarket review and informed consent requirements. During the late twentieth century, statutory acts like the Prescription Drug User Fee Act and the Food and Drug Administration Modernization Act reshaped resources and timelines, while international accords such as the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use affected standards. CDER's evolution reflected responses to public health crises including the HIV/AIDS epidemic, the opioid crisis, and the H1N1 pandemic.
CDER operates as a center within the Food and Drug Administration headquartered near Silver Spring, Maryland, reporting to FDA leadership and the Department of Health and Human Services. The center is organized into offices and divisions such as the Office of New Drugs, Office of Generic Drugs, Office of Surveillance and Epidemiology, and Office of Compliance, each parallel to directorates in other agencies like the European Medicines Agency and Health Canada. Leadership has included notable officials who have interacted with Members of United States Congress, advisory committees like the Vaccines and Related Biological Products Advisory Committee, and external stakeholders including the Pharmaceutical Research and Manufacturers of America and PatientsLikeMe. CDER coordinates with academic partners at institutions such as Johns Hopkins University, University of California, San Francisco, and Harvard Medical School on regulatory science initiatives.
CDER's statutory roles derive from authorities granted by the Federal Food, Drug, and Cosmetic Act and amendments enacted by Congress, implementing regulations codified in the Code of Federal Regulations. Responsibilities include premarket review pursuant to New Drug Applications and Biologics License Applications evaluated under statutes like the Drug Price Competition and Patent Term Restoration Act (Hatch-Waxman), oversight of generic products paralleling decisions before the United States Court of Appeals for the Federal Circuit, labeling regulation comparable to rules in the European Commission, manufacturing inspections analogous to programs by the World Health Organization, and enforcement actions using civil and administrative tools rooted in precedent from cases involving companies such as Pfizer and Johnson & Johnson. CDER issues guidances, safety communications, and coordinates recalls and risk evaluations with entities such as the Centers for Disease Control and Prevention and National Institutes of Health.
The drug approval pipeline managed by CDER begins with preclinical studies often conducted at laboratories affiliated with National Institutes of Health and moves into phased clinical trials overseen by Institutional Review Boards established under the National Research Act. Investigational New Drug applications permit human testing before submission of a New Drug Application, which is reviewed according to standards of substantial evidence derived from randomized controlled trials commonly led by academic centers like Mayo Clinic and Cleveland Clinic. Mechanisms such as expedited programs—Fast Track, Breakthrough Therapy, Accelerated Approval, and Priority Review—originate from legislation and FDA policy and mirror accelerated pathways used by regulators such as the European Medicines Agency. Advisory committee meetings, transparency requirements, patent considerations under the Hatch-Waxman Act, and user fee timelines under the Prescription Drug User Fee Act structure decision-making.
Postmarketing oversight uses pharmacovigilance tools including adverse event reporting systems, Risk Evaluation and Mitigation Strategies, and post-approval studies (Phase IV) often mandated after approval. CDER monitors safety signals from sources such as the Vaccine Adverse Event Reporting System, electronic health records at institutions like Kaiser Permanente, and literature in journals such as The New England Journal of Medicine and The Lancet. Enforcement actions can include safety labeling changes, market withdrawals, and import alerts coordinated with the U.S. Customs and Border Protection. CDER collaborates with international counterparts including the European Medicines Agency, Japanese Pharmaceuticals and Medical Devices Agency, and multilateral organizations like the World Health Organization on global safety surveillance.
CDER sponsors and conducts regulatory science research to improve trial design, biomarker validation, and analytical methods, partnering with entities such as National Institute of Allergy and Infectious Diseases, Biomedical Advanced Research and Development Authority, and academic consortia like the Clinical and Translational Science Awards. The center issues guidance documents that influence industry practices and clinical research, aligning with standards from bodies such as the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use and incorporating methodologies used in systematic reviews by groups like the Cochrane Collaboration. CDER contributes to policy debates involving Congress, the Office of Management and Budget, and nongovernmental organizations including Public Citizen and The Pew Charitable Trusts.
CDER's decisions and policies have faced scrutiny in cases involving approvals, postmarket actions, and perceived regulatory capture, drawing attention from Members of United States Congress, investigative reporting in outlets such as The New York Times and ProPublica, and advocacy by groups like AARP and Consumer Reports. Criticisms have targeted expedited approvals in contexts like oncology and treatments for rare diseases, the balance between innovation and safety highlighted during debates over opioid labeling and approvals involving firms such as Purdue Pharma, and resource allocation under the Prescription Drug User Fee Act. Legal challenges and congressional oversight hearings have shaped reforms and continue to influence the center's operations.